1 / 44

Dante Pascali MD FRCS(C) Urogynecology Divison Head Assistant Professor, University of Ottawa

Challenges in Treatments of Common Urogynecological Conditions Challenges in Obstetrics & Gynecology Kuwait Feb 8, 2017. Dante Pascali MD FRCS(C) Urogynecology Divison Head Assistant Professor, University of Ottawa Canada. Disclosures. Consultant for Pfizer, Astellas and Duchesnay.

conniewalker
Télécharger la présentation

Dante Pascali MD FRCS(C) Urogynecology Divison Head Assistant Professor, University of Ottawa

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Challenges in Treatments of Common Urogynecological Conditions Challenges in Obstetrics & GynecologyKuwait Feb 8, 2017 Dante Pascali MD FRCS(C) Urogynecology Divison Head Assistant Professor, University of Ottawa Canada

  2. Disclosures • Consultant for Pfizer, Astellas and Duchesnay.

  3. Objectives • Develop a better understanding of urogenital atrophy. • Review the work up and treatment of recurrent urinary tract infections. • Review the diagnosis and treatment of interstial cystitis

  4. Urogenital Atrophy • When tissues of the vagina become thinner because of the lack of estrogen. This results in itching, pain during sexual intercourse, and a greater frequency of vaginal infection. • “Genitourinary Symptoms of Menopause” (GSM)

  5. Urogenital atrophy: QOL • Negative effects: • self-esteem 1, 2 • physical activity level 1, 2 • sleep 1 • sexuality 3 • relationship with partner 3 1. Kelleher et al. Curr Opin Obstet Gynecol 1995;7(5):404-8. 2. van der Vaart et al. Neurourol Urodyn 2003;22(2):97-104. 3. Bachman. Int J Fertil Menopausal Stud 1995;40:16-22.

  6. Treatment The ideal option is: • effective • safe • convenient to use • acceptable to patient • inexpensive … because treatment is “forever”

  7. Atrophy: Estrogen • restoration of vaginal cytology 1 •  epithelial thickness 1 •  blood flow 2 •  vaginal fluid secretions 3 1. Semmens. Clin Pract Sex 1990;8(suppl):2-3. 2. Sarrel. Int J Impot Res 1998;10(suppl2):S91-3. 3. Rigg. Int J Fertil 1986;31(suppl3):29-34.

  8. Atrophy: Estrogen Routes of Administration • systemic (oral, transdermal) • local (vaginal) On adequate systemic doses: • 25 – 40 % had vaginal dryness Notelovitz. Int J Gynecol Obstet 1997(suppl1);59:S35-9. Smith & Studd. Br J Hosp Med 1993;49(11):799-808.

  9. Atrophy: Estrogen Vaginal Route • CEE cream • 0.5 gm cream (0.3 mg CEE) (1/4 new applicator) daily x 2 weeks, then 2-3 x week • sustained-release estradiol ring • 2 mg estradiol q 3 months • estradiol tablet • 10 μg estradiol daily x 2 weeks, then 2 x week

  10. Atrophy: Estrogen Clinical Efficacy • vaginal estrogen better than placebo • subjective RR > 90% • objective RR > 85% • no significant differences in efficacy between different products Suckling et al. Cochrane Database Syst Rev 2003;(4):CD001500. Cardozo et al. Obstet Gynecol 1998;92 (4):722-7.

  11. Atrophy: Estrogen Safety: CEE Cream • 0.5 gm cream (0.3 mg CEE) daily x 2 weeks, then 3 x week for 6 months • detectable estradiol levels in 5 /20 • biopsy at week 24 in 18 women • proliferative tissue: 1 /18 • no hyperplasia • no carcinoma Handa et al. Obstet Gynecol 1994;84:215-18.

  12. Atrophy: Estrogen Recommendation: Although systemic absorption of estrogen can occur with local preparations, there is insufficient data to recommend annual endometrial surveillance in asymptomatic women using vaginal estrogens in appropriate doses (LEVEL III - C). Farrell et al, SOGC Clinical Practice Guidelines 2004.

  13. Atrophy: Other Options Vaginal moisturizer • polycarbophil gel: Replens™ Vaginal lubricants • KY Jelly ™ • Astroglide™ • Gyne-Moistrin™ NOT A TREATMENT just a coping strategy

  14. Polycarbophil Gel Clinical Efficacy • one applicator 3 x week x 12 weeks •  vaginal fluid 1, 2 •  elasticity 1 •  vaginal pH 1 • no cytologic epithelial change 3 1. Nachtigill. Fertil Steril 1994;61(1):178-80. 2. Bygdeman & Swahn. Maturitas 1996;23(3):259-63. 3. van der Laak. J Clin Path 2002;55(6):446-51.

  15. Regular intercourse maintains normal vaginal blood flow ? Smoking cessation smokers have a higher incidence of atrophy as compared to non-smokers Atrophy: Other Options Leiblum et al. JAMA 1983;249(16):195-8. Kalogeraki et al. In Vivo 1996:10(6):597-600. Karamanidis et al. Clin Exp Obst Gynecol 2001;28(4):274-6.

  16. Atrophy: Other Options No proven symptom benefit • soy isoflavones • Black Cohosh • progesterone cream • Vitamin E Upmalis et al. Menopause 2000;7(4):236-42.

  17. Vaginal energy-based therapy • Radio-frequency or laser energy to the various layers of the vaginal tissue, stimulating collagen regeneration contracture of elastin fibers and neovascularization. • Patients report subjective improvement in symptoms in small case controlled studies • Decreased pH and increased lactobacilli as vaginal flora returns to premenopausal state Pitsouni et al, Maturitas, 2016

  18. Future studies • VELAS – Vaginal Erbium Laser Academy Study • Multicentre Trial • 3 treatments • 1500 post-menopausal patients • Gambracciani et al.

  19. Urinary tract infections • URINALYSIS • Bacteriuria • Hematuria • Pyuria

  20. Microbiology • Escherichia coli is the pathogen in 80 to 85% of uncomplicated UTIs. • Staphylococcus saprophyticus is the cause of most others. • Proteus mirabilis, Klebsiella & Enterococci less common.

  21. Clinical features • Dysuria,frequency,urgency, suprapubic pain,&/or hematuria. • Urethritis & vaginitis may present with dysuria (need to R/O STIs), Hx of new partner, discharge, pruritis , dyspareunia. External dysuria in the absence of frequency & urgency. • Fever(>38 °C), flank pain, CVA tenderness & nausea or vomiting suggest upper tract infection.

  22. Antibiotic resistance E.coli from uncomplicated cystitis: • 30% are resistant to ampicillin and sulfonamides. • Increasing resistance to trimethoprim and/or TMP-SMX varies according to region, ranges from 10 to 22% in the US, in Europe 9 to 15%. • Resistance to nitrofurantoin among E.coli is < 5%.

  23. Short Course vs. Prolonged Treatment • Several studies have confirmed the effectiveness of three day regimens of trimethoprim, TMP-SMX, or a fluoroquinolone for the treatment of acute uncomplicated cystitis. • A meta-analysis that included 32 trials show that three day therapy was similar to prolonged therapy(>= 5 days). • There are no published data in adults that demonstrate nitrofurantoin to be as effective in a single or a 3 day regimen as TMP-SMX, or fluoroquinolone, it should be given for a minimal of 7 days .

  24. Recurrent UTI •  3 UTI / yr • 2 Types: • Bacterial Persistence • Reinfection

  25. Management • Behavioral Modification • Postcoital voiding • Frequent urination (hydration) • Hygiene • Dietary • Cranberry Juice • Vitamin C • Prophylactic antibiotics • Low dose continuous • Intermittent (self-start) • Postcoital

  26. Cranberry Juice • Cranberries contain compounds that: • prevent bacteria (E.coli) from adhering to uro-epithelial cells • cause bacteria to be flushed & prevent colonization • (fructose & polymeric compound of unknown nature) • Blueberries also contain polymeric compound • Cranberry: • 200-350 ml 1-3x per day or 1 tablet BID • Decreased incidence of UTI vs. placebo Kontiokari et al. BMJ 2001;322(7302):1571.

  27. Antimicrobial prophylaxis • The choice of antibiotic should be based on susceptibility of the strains causing the previous UTIs & any history of drug allergy. • Before any prophylaxis is initiated eradication of the previous infection must be ensured by obtaining a negative culture 1 to 2 weeks after treatment.

  28. Postcoital prophylaxis • May be more efficient & acceptable method in women whose UTI appears to be related to intercourse. • In a randomized trial, postcoital cipro was as effective as daily cipro in sexually active women. • The preferred regimen is a single dose of cephalexin 250mg or nitrofurantoin 50mg.

  29. Self-treatment • Three studies have shown that UTI can be accurately diagnosed by women 85 to 95% of the time. • This strategy should be restricted to women who have documented UTIs, motivated, compliant, and have good relationship with their MD.

  30. Prophylaxis in post menopausal women • In one randomized ,double blind, placebo-controlled trial of 95 post menopausal women with recurrent UTI, intravaginal estriol cream for 8 months significantly reduced the incidence of UTI compared to placebo (0.5 vs. 5.9 episode per patient per year).

  31. Estrogen Observations • restoration of vaginal flora •  vaginal pH Raz & Stamm. N Eng J Med 1993;329:753-6.

  32. Estrogen Clinical Efficacy • 5.9 UTI/yr placebo versus 0.5 UTI/yr intravaginal estriol 1 • increased interval time before next UTI (estradiol ring versus placebo) 2 • benefit of estrogen over placebo (OR 2.51, CI 1.48-4.25) 3 1. Raz & Stamm. N Eng J Med 1993;329:753-6. 2. Eriksen. Am J Obstet Gynecol 1999;180(5):1072-9. 3. Cardozo et al. Int J Urogynecol Pelvic Floor Dysfunct 2001;12(1):15-20.

  33. Interstitial Cystitisshould be suspected in : • Hx of recurrent UTI with negative cultures. • Dx of OAB with no incontinence & not responding to anticholinergics. • Pain or frequency with sexual activity. • Chronic pelvic pain.

  34. PUF questionnaire • Validated pelvic pain and urgency/frequency patient symptom scale • Total score ranges from 1 to 35. PUF score correlates +ve PST. A total score of 10-14 = 74% likelihood of positive PST; 15-19 = 76%; 20+ = 91% potassium positive

  35. PUF Scale

  36. Potassium sensitivity test (PST) • A +ve PST is a definitive evidence of IC in a patient with –ve culture & no Hx of Ca , radiation, or chemical cystitis, but a –ve test doesn’t R/O the possibility, 20 to 25 % of IC test -ve because the intermittent nature of IC. • PST is the only diagnostic test for IC. • PST 78% sensitive & 98% specific.

  37. Cystoscopy & biopsy • Positive cystoscopic findings are only seen advanced disease , thus it is no longer considered gold standard for diagnosis & is not mandatory. • Cystoscopy has 60% rate of under diagnosis it’s done to exclude other pathology. • There are no histological pathognomonic features of IC, therefore biopsy is not recommended.

  38. Urodynamic Studies • Optional , not specific for diagnosis of IC • Findings include sensory urgency <125 cc & decreased functional capacity <300 cc. • Involuntary contractions occur in 25-28% of patients.

  39. Treatment of IC • Refer to an expert. • Dietary modification. • Tricyclic antidepressants. • Antihistamine Tx. • Cysta-Q Tx (quercetin, bromelain and papain) • Pentosan polysulfate sodium (Elmiron) • Bladder hydrodistension • Intravesical DMSO or heparin

  40. Take Home Message • Local estrogen can significantly improve QOL. • Local estrogen is safe and efficacious. • Recurrent urinary tract infections should be treated with a step-wise approach. • IC is a difficult diagnosis to make, but has several viable treatment options.

More Related